ChemicalBook > CAS DataBase List > galiximab
galiximab
- Product Name
- galiximab
- CAS No.
- 357613-77-5
- Chemical Name
- galiximab
- Synonyms
- Idec-114;Idec 114;galiximab;Galiximab [inn];Unii-S9ox9692zb;Galiximab (anti-CD80);Research Grade Galiximab;Anti-cd80 monoclonal antibody;Research Grade Galiximab(DHE03401);Immunoglobulin G1, anti-(human cd80 (antigen)) (human-macaca irus monoclonal idec-114 heavy chain), disulfide with human-macaca irus monoclonal idec-114 lamda chain, dimer
- CBNumber
- CB21856048
- Formula Weight
- 0
- MOL File
- Mol file
More
Less
galiximab Property
- form
- Liquid
- color
- Colorless to light yellow
galiximab Preparation Products And Raw materials
Raw materials
Preparation Products
More
Less
galiximab Suppliers
- Tel
- 4000-027-021 |24 +86-13986109188 | +86-15623472865 | +81-08033611988
- Fax
- +86-27-87599188
- Country
- China
- ProdList
- 1493
- Advantage
- 55
- Tel
- Fax
- -
- eric_feng1954@126.com
- Country
- China
- ProdList
- 9248
- Advantage
- 55
- Tel
- 021-61312847; 18021002903
- Fax
- QQ:3008007432
- 3008007409@qq.com
- Country
- China
- ProdList
- 71826
- Advantage
- 60
- Tel
- 177-54423994 17754423994
- Fax
- QQ:2853530913
- 2853530910@QQ.com
- Country
- China
- ProdList
- 8000
- Advantage
- 62
- Tel
- 15817493340
- 981810490@qq.com
- Country
- China
- ProdList
- 1566
- Advantage
- 58
- Tel
- 027-65317797 15926423062
- Fax
- QQ:422450190
- 422450190@qq.com
- Country
- China
- ProdList
- 10308
- Advantage
- 58
- Tel
- 4008200310
- marketing@tsbiochem.com
- Country
- China
- ProdList
- 24961
- Advantage
- 58
- Tel
- 027-65279366 18108604356
- products@biolabreagent.com
- Country
- China
- ProdList
- 9868
- Advantage
- 58
- Tel
- 13720134139 086-15871494362 13720134139
- orders@jknbiochem.com
- Country
- China
- ProdList
- 6762
- Advantage
- 58
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Country
- China
- ProdList
- 11973
- Advantage
- 58
357613-77-5, galiximabRelated Search:
Cetrelimab
Omalizumab
Evolocumab
Omburtamab
Volociximab
Camrelizumab
Amatuximab
Eptinezumab
Telisotuzumab
Ublituximab